Outcomes of the study
weight loss
SECONDARY
The primary endpoint was the change in MMDs at weeks 5–8 compared to baseline. Secondary endpoints encompassed change in MMDs at weeks 9–12 and 21–24 compared to baseline, and change in monthly analgesic intake, VAS, HIT-6 and SF-36 scores at weeks 5–8, 9–12 and 21–24 compared to baseline. Other secondary enpoints were changes in antropometric data, durability of weight loss maintenance, effects on circulating lymphocytes and inflammatory markers, and changes in plasma aldosterone and renin levels before and after VLCKD or HBD treatment at weeks 8 and 12.